Bibliography
- CDC. Asthma’s impact on the nation. Data from the CDC national asthma control program 2012
- Kobayashi M, Takeda K, Murata S, et al. Pharmacological Characterization of KUR-1246, a Selective Uterine Relaxant. J Pharmacol Exp Ther 2001;297(2):666-71
- Inoue Y, Yoshizato T, Kawarabayashi T. Investigation of beta2-adrenoceptor subtype selectivity and organ specificity for bedoradrine (KUR-1246), a novel tocolytic beta-adrenergic receptor stimulant. J Obstet Gynaecol Res 2009;35(3):405-13
- Furihata Y, Kobayashi M, Kojima M, et al. Effects of KUR-1246, a selective uterine relaxant, on transplacental passage and transmigration to milk. J Obstet Gynaecol Res 2006;32(1):4-9
- Sadler BM, Dunton AW, Kitt E, et al. Pharmacokinetics and pharmacodynamics of MN-221, a novel, highly selective beta2-adrenergic agonist for treatment of acute chronic obstructive pulmonary disease. Chest 2010;138(4_MeetingAbstracts):471A
- Sadler BM, Dunton AW, Feldman M, et al. Pharmacokinetic (pk) and pharmacodynamic (pd) modeling and simulation support the novelty of mn-221, a highly selective beta2-adrenergic receptor agonist for treatment of acute asthma. Chest 2010;138(4_MeetingAbstracts):168A
- Matsuda K, Makhay M, Johnson K, Iwaki Y. Evaluation of bedoradrine sulfate (MN-221), a novel, highly selective beta2-adrenergic receptor agonist for the treatment of asthma via intravenous infusion. J Asthma 2012;49(10):1071-8
- Study Evaluating the Safety and Effects of MN-221 in Subjects With Moderate to Severe Asthma. Study Evaluating the Safety and Effects of MN-221 in Subjects With Moderate to Severe Asthma. 2011. Available from: www.clinicaltrials.gov
- Evaluate the safety of MN-221 in subjects with stable moderate to severe chronic obstructive pulmonary disease (COPD). 2010. Available from: www.clinicaltrials.gov
- Safety study to evaluate MN-221 in chronic obstructive pulmonary disease (COPD) patients. Safety study to evaluate MN-221 in chronic obstructive pulmonary disease (COPD) patients. 2011. Available from: www.clinicaltrials.gov
- Matsuda K, Iwaki Y, Feldman M, Dunton AW. Evaluation of MN-221 (Bedoradrine), a novel, highly selective beta2-adrenergic receptor agonist in mild to moderate asthma via intravenous infusion. chest 2010;138(Suppl):167A
- Iwaki Y, Matsuda K, Feldman M, Bradley SP. Comparison of administration rates of mn-221 (bedoradrine), a novel, highly selective beta2-receptor agonist in patients with stable mild to moderate asthma. Chest 2010;138(4_MeetingAbstracts):165A
- Study evaluating the safety and effects of MN-221 in subjects experiencing an acute exacerbation of asthma. 2012. Available from: www.clinicaltrials.gov
- MediciNova Reports Results of a Phase 2b Clinical Trial of MN-221 in Asthma Exacerbations. 2012. Available from: http://globenewswire.com/news-release/2012/05/23/477618/257093/en/MediciNova-Reports-Results-of-a-Phase-2b-Clinical-Trial-of-MN-221-in-Asthma-Exacerbations.html#sthash.V1rsK6QS.dpuf
- Pearle J, Iwaki Y, Dunton AW, et al. Intravenous mn-221, a novel, highly selective beta2-adrenergic receptor agonist, improves lung function in stable moderate to severe chronic obstructive pulmonary disease patients. Chest 2010;138(4_MeetingAbstracts):487A
- Johnson K, Iwaki Y, Feldman M, et al. Cardiovascular effects of mn-221 (bedoradrine) administered with albuterol in dogs. Chest 2010;138(4_MeetingAbstracts):174A
- Study evaluating the safety and effects of MN-221 in subjects experiencing an acute exacerbation of asthma. Study evaluating the safety and effects of MN-221 in subjects experiencing an acute exacerbation of asthma. 2011. Available from: www.clinicaltrials.gov [Last accessed 14 April 2014]